This study was conducted to describe the real-world hospital length of stay in patients treated with all of the U.S. Food and Drug Administration approved direct oral anticoagulants (DOACs) versus warfarin for new-onset venous thromboembolism (VTE) at a large, tertiary, academic medical center. A retrospective cohort analysis of all adult patients diagnosed with acute onset VTE was conducted. Of the 441 patients included, 261 (57%) patients received DOACs versus 180 (41%) patients received warfarin. In the DOAC group, a total of 92 (35%) patients received rivaroxaban, followed by 83 (32%) patients received apixaban, 50 (19%) patients received dabigatran, and 36 (14%) patients received edoxaban. Patients initiated on DOACs had a statistically significant shorter hospital length of stay compared to patients initiated on warfarin (median 3 days, [IQR 0–5] vs. 8 days [IQR 5–11], P < 0.05). Despite the shorter hospital length of stay in patients receiving DOACs, the overall reported differences between the DOACs group and the warfarin group in terms of recurrent VTE, major bleeding, intracranial bleeding, and gastrointestinal bleeding at 3 and 6 months were deemed to be statistically insignificant.
Venous thromboembolism Direct oral anticoagulants (DOACs) Warfarin Pulmonary embolism Deep vein thrombosis Hospital length of stay
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
The author has no conflicts of interest to declare.
Research involving human and animal participants
This article does not contain any studies with human participants or animals performed by any of the authors. The study was based on patients receiving treatment. IRB waived the need for informed consent because of all patients data were de-identified.
Buller HR et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRefPubMedGoogle Scholar
Agnelli G et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefPubMedGoogle Scholar
Buller HR et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415CrossRefPubMedGoogle Scholar
Badreldin H et al (2017) Evaluation of anticoagulation selection for acute venous thromboembolism. J Thromb Thrombolysis 43:74–78CrossRefPubMedGoogle Scholar
Saint CA et al (2017) Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Med 5:2050312117719628CrossRefPubMedPubMedCentralGoogle Scholar
Basto AN et al. (2017) Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. J Thromb Thrombolysis 45:51–55Google Scholar
Bookhart BK et al (2014) Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ 17:691–695CrossRefPubMedGoogle Scholar
Roberts KM et al. (2015) Length of stay comparison between rivaroxaban and warfarin in the treatment of pulmonary embolism: results from a real-world observational cohort study. Thrombosis 2015:414523CrossRefPubMedPubMedCentralGoogle Scholar